Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERENOME, INC.CTYX · Entity 7637 | Chief Medical Officer | March 08, 2017 | March 17, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERENOME, INC.
Report date March 08, 2017 · Filed March 17, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2027-03-08 | Direct | 31,100 |
Reported balance
After 2017-03-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-03-08 · Grant · Acquired 31,100 · Balance 31,100 F1: Twenty-five percent (25%) of the option shares shall vest and become exercisable on March 8, 2018 with the remaining option shares vesting and becoming exercisable in thirty-six (36) consecutive monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the option shares shall vest and become exercisable on March 8, 2018 with the remaining option shares vesting and becoming exercisable in thirty-six (36) consecutive monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2017 Filed Mar 10, 2017 22:58 UTC | CERENOME, INC. CTYX · Entity 7637 | GrantIncentive Stock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-019945 · doc4.xml · derivative · entry 1 Marino Mark · CIK 0001681754 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2027-03-08 F1 · derivative.exercise_date: Twenty-five percent (25%) of the option shares shall vest and become exercisable on March 8, 2018 with the remaining option shares vesting and becoming exercisable in thirty-six (36) consecutive monthly installments. Read SEC document |
| March 08, 2017 Filed Mar 17, 2017 21:10 UTC Amendment | CERENOME, INC. CTYX · Entity 7637 | GrantIncentive Stock Option (right to buy) · Derivative | 31,100 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-021463 · doc4a.xml · derivative · entry 1 Marino Mark · CIK 0001681754 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 Underlying: Common Stock · 31,100 shares Expires 2027-03-08 F1 · derivative.exercise_date: Twenty-five percent (25%) of the option shares shall vest and become exercisable on March 8, 2018 with the remaining option shares vesting and becoming exercisable in thirty-six (36) consecutive monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.